The U.S. vaccine policy landscape is facing more turmoil with the upcoming two-day meeting of the Advisory Committee on Immunization Practices (ACIP) to the Centers for Disease Control and Prevention. This independent panel of experts traditionally meets three times a year to make science-based recommendations about vaccine usage. However, the Trump administration’s interference in science and public health has disrupted the committee. Former CDC director Susan Monarez recently testified about being pushed out of office for not supporting attacks on vaccines without evidence. Furthermore, Robert F. Kennedy, Jr., an anti-vaccine activist, fired the panel’s members and appointed new ones just days before the meeting.
The concern among experts is that the new ACIP members may continue to limit access to vaccines, as one in six parents in the U.S. reports delaying or skipping vaccines for their children. Pediatric infectious diseases specialist Paul Offit expressed his fears for children’s health in the country, citing Kennedy’s efforts to make vaccines less available, affordable, and more feared.
The ACIP meeting on September 18 and 19 will focus on three vaccines: the combined measles, mumps, rubella, and varicella vaccine, the hepatitis B vaccine, and this year’s updated COVID shots. The agenda for the meeting is shorter than usual, with concerns raised by public health experts that attacks on the childhood vaccine schedule may be institutionalized, impacting the effectiveness of disease prevention.
During the meeting, the committee voted against recommending the single combination MMRV vaccine before age four, citing concerns about seizures following the combined vaccination in younger age groups. The committee also deliberated on the hepatitis B vaccine, affirming that all pregnant women should be tested for the infection. However, the recommendation to remove the birth dose for infants born to virus-negative parents was tabled indefinitely due to wording concerns.
For COVID vaccines, the committee unanimously recommended vaccination for individuals older than six months based on shared clinical decision-making. There was a tie vote on requiring a prescription for COVID vaccination, with concerns raised about limiting access to vaccines. The committee also discussed rare adverse incidents reported in children after vaccination, including unconfirmed reports of deaths, emphasizing the importance of evaluating safety data to determine the need for any changes to existing vaccines.
In conclusion, the ACIP meeting highlights the ongoing challenges in U.S. vaccine policy and the importance of evidence-based decision-making in public health. Experts stress the significance of vaccination in preventing diseases and protecting public health, especially in the face of misinformation and anti-vaccine sentiments.
